Por favor, use este identificador para citar o enlazar este ítem: https://doi.org/10.14670/HH-18-130

Registro completo de metadatos
Campo DCValorLengua/Idioma
dc.contributor.authorSato, Ai-
dc.contributor.authorMiki, Yasuhiro-
dc.contributor.authorTakagi, Kiyoshi-
dc.contributor.authorYoshimura, Ayano-
dc.contributor.authorHara, Mizuki-
dc.contributor.authorIshida, Takanori-
dc.contributor.authorSasano, Hironobu-
dc.contributor.authorSuzuki, Takashi-
dc.date.accessioned2022-10-27T08:55:42Z-
dc.date.available2022-10-27T08:55:42Z-
dc.date.issued2019-
dc.identifier.citationHistology and Histopathology Vol. 34, nº 12 (2019)es
dc.identifier.issn0213-3911-
dc.identifier.issn1699-5848-
dc.identifier.urihttp://hdl.handle.net/10201/124948-
dc.description.abstractBackground. Cytochrome c1 (CYC1) is a heme-containing subunit of mitochondria complex III and is mainly involved in cellular energy production. A recent study has demonstrated that CYC1 was overexpressed in breast carcinoma tissues and induced proliferation, migration and invasion of estrogen receptor (ER)-negative breast carcinoma cells. However, the clinical significance of CYC1 protein remains largely unclear in invasive breast carcinoma, and biological functions of CYC1 have not been reported in ER- positive breast carcinoma cells. Materials and methods. We immunolocalized CYC1 in 172 invasive breast carcinomas and evaluated its clinical significance according to the ER-status. Subsequently, we examined the effects of CYC1 on proliferation, glycolysis and chemosensitivity to paclitaxel, which is one of the most common chemotherapeutic agents in breast cancer, in ER-positive breast carcinoma cells (MCF7 and T47D). Results. CYC1 immunoreactivity was detected in 47% of ER-positive cases and 30% of ER-negative cases. Immunohistochemical CYC1 status was inversely associated with Ki67 in ER-positive cases, and it was a significantly favorable prognostic factor for both disease-free and breast cancer-specific survival of the patients. On the other hand, no significant association was detected between CYC1 status and clinico- pathological factors in ER-negative cases. In in vitro experiments, MCF7 and T47D cells transfected specific siRNA for CYC1 significantly increased cell proliferation activity, L-lactate production and cell viability after paclitaxel treatment. Conclusion. These results suggest that CYC1 inhibits cell proliferation, glycolytic activity and increases chemosensitivity to paclitaxel in ER-positive breast carcinoma cells and that CYC1 status is a potent favorable prognostic factor in ER-positive breast cancer patientses
dc.formatapplication/pdfes
dc.format.extent11es
dc.languageenges
dc.publisherUniversidad de Murcia, Departamento de Biologia Celular e Histiologiaes
dc.relationSin financiación externa a la Universidades
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectBreast Neoplasmses
dc.subjectChemosensitivityes
dc.subjectCytochrome c1es
dc.subjectEstrogen Receptores
dc.subjectPrognosises
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncologíaes
dc.titleCytochrome c1 as a favorable prognostic marker in estrogen receptor-positive breast carcinomaes
dc.typeinfo:eu-repo/semantics/articlees
dc.identifier.doihttps://doi.org/10.14670/HH-18-130-
Aparece en las colecciones:Vol.34,nº12 (2019)

Ficheros en este ítem:
Fichero Descripción TamañoFormato 
Sato-34-1365-1375-2019.pdf2,45 MBAdobe PDFVista previa
Visualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons